Have a personal or library account? Click to login
A Comparative Analysis of the Effects of Haloperidol and Dexmedetomidine on QTc Interval Prolongation during Delirium Treatment in Intensive Care Units Cover

A Comparative Analysis of the Effects of Haloperidol and Dexmedetomidine on QTc Interval Prolongation during Delirium Treatment in Intensive Care Units

Open Access
|Jul 2024

Figures & Tables

Fig. 1

Indications for hospitalization in the intensive care unit.
Indications for hospitalization in the intensive care unit.

Fig. 2

Forest plot graph of the relationship between baseline characteristics of patients and QTc prolongation after drug infusions.
Forest plot graph of the relationship between baseline characteristics of patients and QTc prolongation after drug infusions.

Fig. 3.

A Patients with QTc interval above 450 msec after drug infusions, B: Patients with >20 msec prolongation in QTc interval after drug infusions.
A Patients with QTc interval above 450 msec after drug infusions, B: Patients with >20 msec prolongation in QTc interval after drug infusions.

Fig. 4

The effect of dexmedetomidine (A) and haloperidol (B) treatment on QT and QTc interval in box plot graph.
The effect of dexmedetomidine (A) and haloperidol (B) treatment on QT and QTc interval in box plot graph.

Blood pressure, heart rate, oxygen saturation, sedation depth, and QT interval before and after haloperidol and dexmedetomidine treatment_

Patient characteristicsDexmedetomidine (n=45)Haloperidol (n=45)

Pre-infusionPost-infusionP valuePre-infusionPost-infusionP value
Systolic blood pressure (mmHg)117.6±3.4113.2±27.20.345137.5±24.4117.4±26.0<0.001*
Heart rate (bpm)98.5±25.7100.4±23.10.66497.5±19.788.5±27.80.014*
Pulse oximeter oxygen saturation (SpO2) (%)96.2±2.296.9±2.30.004*97.2±2.397.0±2.20.585
Ramsay Sedation scale1.3±0.81.4±0.60.2041.5±1.01.8±1.00.015*
RASS2.5±1.51.2±1.2<0.001*2.0±2.20.40±1.5<0.001*

Patient characteristics according to treatment groups_

Patient characteristicsDexmedetomidine (n=45)Haloperidol (n=45)P value
Age (years) (mean±SD)77.2±9.073.2±15.80.14
Sex (male%)48.951.10.84
BMI (kg/m2) (mean±SD)28.0±6.628.0±6.90.95
APACHE II (mean±SD)32.8±5.332.0±7.00.58
GCS (mean±SD)9.1±2.29.4±1.30.48
Hospitalization period (day) (median±SD)16±1321±340.016*
Time to delirium (hour) (median±SD)48±197120±1460.27
Ventilator duration (day) (median±SD)14±13.421±34.70.013*
Drug infusion time (hour) (median±SD)108±95.2126±75.50.94
Total amount of drug (mg) (median±SD)3.8±1.6150±107.4<0.001*
In-hospital mortality (%)48.957.80.4
Pre-infusion SBP (mmHg) (mean±SD)117.5±23.4137.5±24.4<0.001*
Pre-infusion HR (bpm) (mean±SD)98.5±25.697.5±19.70.83
Pre-infusion SpO2 (mean±SD)96.2±2.297.2±2.30.04*
Pre-infusion Ramsay SS (median±SD)1.3±0.81.5±1.00.26
Pre-infusion RASS score (median±SD)2.45±1.451.96±2.20.18
Pre-infusion QT interval (ms) (mean±SD)360.5±81.7363.2±51.10.85
Pre-infusion QTc interval (ms) (mean±SD)409.4±63.1427.3±45.80.99
DOI: https://doi.org/10.2478/jccm-2024-0027 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Language: English
Page range: 222 - 231
Submitted on: Sep 15, 2023
Accepted on: Jun 15, 2024
Published on: Jul 31, 2024
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Ali Haspolat, Fuat Polat, Ali Şefik Köprülü, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.